Vimarsana
Biggest News Aggregation in the World

Page 21 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Analysts Offer Predictions for Compugen Ltd.'s Q1 2023 Earnings (NASDAQ:CGEN) - Vimarsana News

Analysts Offer Predictions for Compugen Ltd.'s Q1 2023 Earnings (NASDAQ:CGEN)

Compugen Ltd. (NASDAQ:CGEN – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for shares of Compugen in a research note issued to investors on Monday, February 27th. Jefferies Financial Group analyst C. Howerton expects that the biotechnology company will earn ($0.14) per share for […]

Compugen: Q4 Earnings Snapshot - Vimarsana News

Compugen: Q4 Earnings Snapshot

HOLON, Israel (AP) — HOLON, Israel (AP) — Compugen Ltd. (CGEN) on Monday reported a loss of $3.1 million in its fourth quarter. The Holon, Israel-based company said it had a loss of 4 cents per share.

Source: apnews.com
Compugen Ltd.: Compugen Reports Fourth Quarter and Full Year 2022 Results - Vimarsana News

Compugen Ltd.: Compugen Reports Fourth Quarter and Full Year 2022 Results

On track to dose the first patients in MSS CRC and PROC triple combination proof of concept studies in Q1 2023 and Q2 2023, respectively, with the combination of potential first-in-class anti-PVRIG,

Compugen Reports Fourth Quarter and Full Year 2022 Results - Vimarsana News

Compugen Reports Fourth Quarter and Full Year 2022 Results

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and pioneer in computational target...

Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3 - Vimarsana News

Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3

Phase 3 study with rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq:AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902 is expected to start in 2023....